Bosutinib, dasatinib, nilotinib and ponatinib are now listed in the interaction checker as cancer drugs and interactions can be found with all the comedications.
• Bosutinib (Bosulif®) is a protein kinase inhibitor and is indicated for the treatment of chronic myeloid leukemia (BCR-ABL positive).
• Dasatinib (Sprycel®) is a protein kinase inhibitor and is indicated for the treatment of chronic myeloid leukemia (BCR-ABL positive) and precursor cell lymphoblastic leukemia-lymphoma.
• Nilotinib (Tasigna®) is a protein kinase inhibitor and is indicated for the treatment of chronic myeloid leukemia (BCR-ABL positive).
• Ponatinib (Iclusig®) is a protein kinase inhibitor and is indicated for the treatment of chronic myeloid leukemia (BCR-ABL positive).
